Objectives: This study characterizes cytogenetic abnormalities with ultrasound findings to refine counseling following negative cell-free DNA (cfDNA).
| INTRODUCTION
Since its introduction in October of 2011, prenatal genetic screening for aneuploidy through analysis of cell-free DNA (cfDNA) from maternal serum has been established as a sensitive and specific screening method for autosomal trisomy of chromosomes 13, 18, and 21. 1, 2 CfDNA was initially indicated for "high risk" women including those 35 years of age and older, a history of a fetus affected by trisomy of covered chromosomes, a parental balanced Robertsonian translocation involving chromosomes 13 or 21, a fetal ultrasound indicating increased risk of aneuploidy, and positive first or second trimester maternal serum screening results. 3, 4 These indications were based on eligibility criteria in the initial validation studies for cfDNA, not upon epidemiologic studies of population-wide screening. 5 In 2015, the Society for Maternal-Fetal Medicine and the
American College of Obstetricians and Gynecologists published a joint
Committee Opinion with updated recommendations, stating that if an anomaly is identified on ultrasound a diagnostic test should be offered rather than cfDNA. 6 This change followed a paper by Benachi et al noting that in patients with an abnormal ultrasound and low risk cfDNA, 7.9% of the fetuses had an undetected abnormal cytogenetic finding on karyotype (8.5% if the 3 cases of false negative trisomy 18
are accounted for). The characteristics of these remaining chromosomal aberrancies have received less attention. 5 Additionally, microarray findings also contribute to the overall rate of chromosomal disorders among fetuses with ultrasound anomalies. [7] [8] [9] [10] Since the introduction of cfDNA, reports of decreasing numbers of diagnostic procedures have emerged from several facilities. [11] [12] [13] Many women will accept cfDNA but not diagnostic prenatal testing due to the small risks of fetal loss associated with diagnostic procedures. 14, 15 If women with an ultrasound finding forgo diagnostic studies for cfDNA screening, these less common but clinically significant chromosome abnormalities will remain undetected until newborn or pediatric evaluation.
The objective of this study was to examine, in a retrospective fashion, cytogenetic results following diagnostic prenatal testing initiated for an ultrasound finding. The intent was to examine variables influencing the distribution of cytogenetic anomalies detectable by cfDNA and to provide estimates of residual risk for incorporation into patient counseling.
| METHODS
We performed a retrospective cohort study of all fetuses with cytoge- What's already known about this topic?
• Maternal serum screening for aneuploidies has changed since the introduction of cell-free DNA (cfDNA) in 2011.
• Diagnostic testing with chorionic villus sampling or amniocentesis is recommended in the presence of a structural ultrasound finding.
What does this study add?
• When ultrasound findings are present, the rate of cytogenetic anomalies not detectible by cfDNA increases with increasing fetal gestational age.
• The size of first trimester nuchal translucency is inversely related to the likelihood of cfDNA detected aneuploidy.
• 16.3% of cytogenetic abnormalities would likely be missed by cfDNA in the presence of an ultrasound finding. Table 1 ). The mean maternal age was 33.9 (range As seen in Table 4C , there were 21 pregnancies with cfDNAdetectable findings and an isolated second trimester soft marker. Most these cases were trisomy 21; however, there was 1 trisomy 18 case with an isolated choroid plexus cyst in a patient with a high-risk serum screen. In this patient, the ultrasound was done at 17 + 6/7 weeks gestational age, and both hands were reported to be open (Table 4C ).
As seen in Table 4B , when looking at first trimester nuchal translu- Table 4B ). For an isolated first trimester nuchal translucency of 3.0 to 3.49 mm, the chromosome abnormality was detectable by cfDNA in 84.2% (32/38), whereas for an isolated first trimester nuchal translucency of ≥3.5 mm without a cystic hygroma, it was 87.7% (142/162) detectable by cfDNA, and for first trimester cystic hygroma, it was 95.7% (90/94) detectable by cfDNA (Table 4B) .
| DISCUSSION
This study describes the ultrasound findings and prenatal cytogenetic abnormalities in a cohort of 498 patients from January 2005 to Among fetuses with ultrasound findings, 16.3% of clinically relevant karyotypic abnormalities were non-cfDNA detectable. This included 21 fetuses with triploidy. While considered not detectable in our study, some SNP-based platforms provide coverage for triploidy, 25.26 If triploidy is ascertained by the cfDNA platform, our overall rate of not detectable cytogenetic anomalies drops further to 12.0% overall and 7.3% (19/259) following first trimester ultrasound findings.
Secondly, gestational age at recognition of the ultrasound abnormality is related to the likelihood of a cfDNA detectable chromosome abnormality. With first trimester ultrasound findings, the majority of which represent increased nuchal translucency (≥3.0 mm), the occurrence of the common aneuploidies detectable by cfDNA is higher than in the second trimester (87.6% and 80.5% respectively). Lastly, among the studies initiated for second trimester ultrasound findings, the proportion of cytogenetic results considered non-cfDNA detectable did not differ between those with a structural anomaly compared with those with single or multiple soft markers. As our overall sample size with soft markers and a non-cfDNA detectable abnormality is small and our study did not include normal karyotypes, this last finding may have further clinical relevance if replicated in a larger study.
Whether to pursue amniocentesis for definitive diagnosis in the setting of a soft marker and a negative cfDNA will require further investigation with larger populations.
Our analysis of microarray findings is limited by small sample size.
However, the rate of additional abnormality detected in the presence of an ultrasound anomaly (12.6%) is similar to that reported in a recent meta-analysis by Hillman et al (11.2%). 8 While the coverage for microduplications and deletions continues to expand for cfDNA, only 1 of the 12 identified submicroscopic findings in this ultrasound indicated cohort is present on the currently available cfDNA platforms and the sensitivity and specificity is lower than that for whole chromosome changes. The other findings identified in this study by microarray are unlikely to be added to current cfDNA platforms because of their small size or low incidence (Table 2 ). This emphasizes the point that while collectively microarray abnormalities occur at a rate of 1 in 1000, for the majority their location is scattered throughout the genome.
This study was not designed to be an assessment of the performance of cfDNA versus standard screening; many other authors have addressed this question. 2,27.28 Assumptions of detection of aneuploidy by cfDNA were made without correction for sensitivity. As testing cutoffs and methodologies can change, the results presented here represent the gold standard of cytogenetic assessment and can be applied
to future screening models with varying performance. However, modeling of cfDNA performance is less useful than large studies with cfDNA and diagnostic testing. While the detection rate of cfDNA for trisomy 21 is high (99.7%), sensitivities for the remainder of the common aneuploidies and the sex chromosomes are lower (80%-90%), 6.24 As such, the rates established in this study should be P values for differences in trimesters, nuchal translucency, and ultrasound findings across categories were obtained by Chi squared test for categorical variables. NT, nuchal translucency; EIF, echogenic intracardiac focus; first trimester ultrasounds were performed between 11 + 6/7 and 13 + 6/7 weeks gestational age, second trimester ultrasounds were performed between 14 + 0/7 and 27 + 6/7 weeks gestational age.
b Only fetuses with a crown-rump length between 34 and 84 mm and NT ≥ 3.0 mm included in analysis.
data in this study. Additionally, as the initial cohort was defined as those with an abnormal prenatal cytogenetic result, women who terminated based on an abnormal ultrasound alone or those who had postnatal diagnosis were not captured in this study. This could introduce bias and limit the generalizability of our results. This paper represents the experience of a single large cytogenetics lab that serves several hospitals in the greater Boston area, which further limits the generalizability to other populations.
| CONCLUSIONS
In a cytogenetically abnormal cohort ascertained due to ultrasound findings, we found a 16.3% rate of karyotype abnormalities of clinical significance that were non-cfDNA detectable. This rate lowers to 12.0% with triploidy assessment by SNP-based platforms. This rate differs by gestational age with the lowest rate of non-cfDNA detectable aneuploidy in the first trimester (12.4% if triploidy is not detected and 7.3% in triploidy is detected). Abnormal chromosome results in pregnancies with a first trimester cystic hygroma or NT ≥3.5 mm were more likely to be detected by cfDNA than NT 3.0 to 3.5 mm. However, the true rate is likely higher than our estimate as cfDNA has less than 100% sensitivity especially for trisomies 13 and 18 and the sex chromosomes. Microarray analysis further contributes important clinical information with a wider distribution of deletion and duplication aberrancies than available currently through cfDNA.
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